

Dual Tyrosyl-DNA Phosphodiesterase/Topoisomerase Inhibitors

Track Code: 66149

Categories:

- Chemical Engineering
- Pharmaceuticals

Keywords:

- Camptothecin
- Chemical Engineering
- Chemotherapy
- Inhibitors
- Pharmaceuticals
- Topoisomerase

Topoisomerase 1 (TOP1) is an enzyme involved in the replication of DNA. Molecules displaying TOP1 inhibitory function have found clinical applications as well as the frequent subject of research. Another enzyme functioning alongside TOP1 is tyrosyl-DNA phosphodiesterase 1 (TDP1), which repairs DNA lesions. Observations of this enzyme suggest mediating its activity could potentiate the cytotoxic effect of TOP1 inhibitors. TDP1 inhibitory activity has been seen to a limited extent in a handful of compounds, though their potencies, specificities, and pharmacokinetic properties leave much to be desired.

Purdue University researchers have developed a series of novel, low molecular-weight compounds that can act as dual inhibitors of both TOP1 and TDP1. A dual inhibitor of this type would offer significant advantages over individual TOP1 and TDP1 inhibitors alone such as simplification of delivery and bioavailability. In lab tests, the dual inhibitor is an equally potent TOP1 inhibitor as the commercially available camptothecin. These molecules are thought to function by stalling the DNA synthesis phase of the cell cycle, thereby inducing apoptosis, and effectively killing the cell. This drug could work in combination with other chemotherapies to effectively eliminate highly proliferative cell growth in the body.

Advantages:

- First dual inhibitor of TOP1 and TDP1
- Shown to be as cytotoxic to TOP1 as camptothecin
- A potentially more potent chemotherapy agent

Potential Applications:

- Medical/Healthcare

-Pharmaceuticals
-Cancer Treatment

People:

- Cushman, Mark (Project leader)
- Nguyen, Trung Xuan

Intellectual Property:

Application Date: September 29, 2015

Type: CON-Patent

Country of Filing: United States

Patent Number: 9,402,842

Issue Date: August 2, 2016

Application Date: November 10, 2014

Type: DIV-Patent

Country of Filing: United States

Patent Number: 9,175,002

Issue Date: November 3, 2015

Application Date: March 15, 2013

Type: Utility Patent

Country of Filing: United States

Patent Number: 8,912,213

Issue Date: December 16, 2014

Application Date: April 13, 2012

Type: Provisional-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: otcip@prf.org